Mibeg

Iobenguane (I-123), the active ingredient in Mibeg, is a radiopharmaceutical presented as a solution for injection for intravenous use. It is used for diagnostic imaging of neuroendocrine tumors and cardiac sympathetic innervation. GNH USA supplies Mibeg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and clinics worldwide.

Mibeg is a radiopharmaceutical that targets adrenergic tissue for diagnostic imaging of several conditions.

Neuroblastoma imaging: enables visualization of tumor uptake for staging and treatment planning. Pheochromocytoma detection: helps locate catecholamine‑producing adrenal tumors. Paraganglioma imaging: provides functional assessment of extra‑adrenal paraganglial lesions. Cardiac sympathetic innervation assessment: evaluates sympathetic nerve activity in the heart for risk stratification.

Mibeg may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Transient flushing - Headache - Injection‑site pain or irritation - Mild hypotension - Dizziness

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Marked hypotension or cardiovascular collapse - Radiation‑induced thyroiditis - Pulmonary edema - Severe arrhythmia - Significant radiation exposure to staff if handling precautions are not followed

Mibeg requires careful consideration of patient-specific factors and handling requirements.

Pregnancy: Use only if the diagnostic benefit outweighs potential fetal radiation risk. Breastfeeding: Avoid; the radiotracer may be secreted in milk. Renal impairment: Monitor renal function; altered clearance may affect image quality. Thyroid function: Assess baseline thyroid status; consider blocking agents if necessary. Hypersensitivity: Contraindicated in patients with known allergy to Iobenguane or iodine. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iobenguane can interact with drugs that affect norepinephrine pathways or iodine metabolism.

Major Interactions (Avoid): - Sympathomimetic agents (may alter tracer uptake) - Thyroid blocking agents such as perchlorate (reduce tracer accumulation) - High‑dose iodine compounds (compete for uptake)

Moderate Interactions (Monitor Closely): - Antihypertensive medications (potential additive hypotensive effect) - Diuretics (may influence renal clearance) - Beta‑blockers (possible impact on tracer distribution)